Blocking certain immune cells helped mice with a midline brain tumor
Original title: Histone H3K27M variants determine myeloid subset dependencies and immune reprogramming in diffuse midline glioma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done in animals, not people. Most findings at this stage never become treatments.
This was only done in mice.
The short version
In mice, blocking a certain immune cell helped some live longer.
What was studied. Researchers studied mice with diffuse midline glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary, a fast growing brain tumor. They used gene editing to keep certain immune cells, called monocytes, out of the tumor.
What they found. Mice with the H3.1K27M type of tumor lived longer when those cells were kept out. The other immune cells inside the tumor settled into a calmer, more normal state. Mice with the H3.3K27M type did not depend on those cells, so blocking them did not help.
What this means, and what it doesn't
What it could mean: It points to a possible target for future treatments. It also suggests that different types of this tumor may need different treatments.
What it doesn't mean: This work was done in mice, not in people. There is no drug or treatment from it that a person can get. Blocking these cells also did not make radiation work better in the mice. This is early lab research, far from everyday care. It is not a cure, and it is not a promise of one.
Source: PubMed, August 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.